A second-generation MEK inhibitor PD0325901 was also selected using machine learning methods as a drug for breast cancer treatment [75] and amplified anti-proliferative and anti-clonogenic effects of gefitinib and AT7867 by activating apoptosis in TNBC cells [76]. This evidence concerns the gene MAP2K7 and breast carcinoma.